Lumos Diagnostics Boosts FY26 Revenue 6% on FebriDx Growth and CLIA Milestones

FebriDx Drives Revenue and Market Expansion

Lumos Diagnostics (ASX:LDX) closed FY26 with a 6% revenue increase to US$13.2 million, powered by an 875% leap in sales of its flagship FebriDx® rapid diagnostic test. The surge followed a landmark U.S. FDA CLIA waiver granted in March 2026, which expanded FebriDx’s addressable market approximately 15-fold to over 300,000 U.S. healthcare locations. This regulatory milestone unlocked immediate milestone payments totaling US$5.5 million from PHASE Scientific and BARDA, underpinning the company’s commercial momentum.

FebriDx is now actively ordered and used at more than 170 healthcare sites across 24 states, including a significant rollout at WellStreet Urgent Care’s 44 locations and commitments from multiple top 100 urgent care groups. Early reimbursement success has been strong, with over 90% of submitted claims paid, often exceeding Medicare’s benchmark rate of US$41.38 per test. This bodes well for establishing a sustainable economic model across providers, distributors, and Lumos itself.

Mixed Performance in Product and Services Segments

While FebriDx sales soared to US$3.9 million for the year, other product lines faced headwinds. Sales of the CorDx Flu A/B/COVID combo test, introduced to replace the less competitive ViraDx®, fell short of prior levels, dragging product revenue down 49% in Q4 compared to the previous corresponding period. The services division saw a 16% decline in full-year revenue to US$8.9 million, primarily due to an extended timeline for the Hologic fFN diagnostic project, now pushed out to June 2028. This extension reduced amortization income from the Hologic IP license fee from US$4.6 million in FY25 to US$1.4 million in FY26.

Nonetheless, excluding the IP license fee impact, contract research and development revenue grew 24%, reflecting ongoing activity across 12 customer projects including collaborations with Micro-Pak, TeleMedVet, and Aptatek Biosciences.

Cash Flow Strength and Debt-Free Position

Lumos generated an operating cash inflow of US$2.7 million in Q4 FY26, reversing a prior year outflow, supported by higher customer receipts including the US$5 million PHASE prepayment linked to the CLIA waiver. The company ended the quarter with a robust cash balance of US$15.4 million.

Post-quarter, Lumos fully repaid and closed its A$5 million secured loan facility with major shareholders Tenmile and Ryder Capital, leaving the company debt-free and with released security interests. Capital expenditure included US$2.1 million on expanding manufacturing capacity at its Carlsbad facility, with completion expected by November 2026.

Advancing Paediatric Study and Commercial Priorities

In parallel with commercial expansion, Lumos is progressing a BARDA-supported paediatric study to extend FebriDx use to children aged 2 to 12 in CLIA waived settings. The company recently completed Milestone #7 with 250 patients enrolled, triggering a US$670,000 payment and bringing cumulative BARDA milestone receipts to US$2.6 million. This study aims to increase FebriDx’s U.S. addressable market by an estimated 15–20% once regulatory clearance is obtained.

CEO Doug Ward highlighted that commercial adoption is tracking ahead of expectations and emphasised efforts to increase market awareness, expand site adoption, and support reimbursement ahead of the upcoming U.S. respiratory season. Lumos is also building out its commercial infrastructure through partnerships with PHASE, PROspectus, AcuityMD, MTMC, and marketing agency CG Life to accelerate growth in the outpatient segment.